ATE453723T1 - Psoriasin-expression durch brustepithelzellen - Google Patents

Psoriasin-expression durch brustepithelzellen

Info

Publication number
ATE453723T1
ATE453723T1 AT02806283T AT02806283T ATE453723T1 AT E453723 T1 ATE453723 T1 AT E453723T1 AT 02806283 T AT02806283 T AT 02806283T AT 02806283 T AT02806283 T AT 02806283T AT E453723 T1 ATE453723 T1 AT E453723T1
Authority
AT
Austria
Prior art keywords
dcis
high grade
hid
risk
epithelial cells
Prior art date
Application number
AT02806283T
Other languages
English (en)
Inventor
Kornelia Polyak
Charlotta Enerbaeck
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE453723T1 publication Critical patent/ATE453723T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT02806283T 2001-12-31 2002-12-30 Psoriasin-expression durch brustepithelzellen ATE453723T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34574001P 2001-12-31 2001-12-31
PCT/US2002/041795 WO2003057159A2 (en) 2001-12-31 2002-12-30 Psoriasin expression by breast epithelial cells

Publications (1)

Publication Number Publication Date
ATE453723T1 true ATE453723T1 (de) 2010-01-15

Family

ID=23356293

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02806283T ATE453723T1 (de) 2001-12-31 2002-12-30 Psoriasin-expression durch brustepithelzellen

Country Status (9)

Country Link
US (2) US7465553B2 (de)
EP (1) EP1470239B1 (de)
JP (1) JP2005526233A (de)
AT (1) ATE453723T1 (de)
AU (1) AU2002367317A1 (de)
CA (1) CA2472163C (de)
DE (1) DE60234958D1 (de)
ES (1) ES2338774T3 (de)
WO (1) WO2003057159A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US9856533B2 (en) * 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
GB0412620D0 (en) * 2004-06-05 2004-07-07 Univ Belfast BRCA1 markers
US8379960B2 (en) * 2009-03-30 2013-02-19 Ge Healthcare Bio-Sciences Corp. System and method for distinguishing between biological materials
WO2010118324A2 (en) 2009-04-09 2010-10-14 Nuclea Biotechnologies, LLC Antibodies against fatty acid synthase
US8685891B2 (en) 2009-08-27 2014-04-01 Nuclea Biotechnologies, Inc. Method and assay for determining FAS expression
WO2012079059A2 (en) 2010-12-09 2012-06-14 Biotheranostics, Inc. Post-treatment breast cancer prognosis
ES2639227T3 (es) * 2013-04-09 2017-10-25 Lykera Biomed S.A. Anticuerpos anti S100A7 para el tratamiento y diagnóstico de cáncer
JP2017090102A (ja) * 2015-11-05 2017-05-25 和光純薬工業株式会社 浸潤性乳癌の判定法
JP2017090103A (ja) * 2015-11-05 2017-05-25 和光純薬工業株式会社 非浸潤性乳癌の判定法
MX2018005867A (es) 2015-11-13 2018-09-21 Biotheranostics Inc Integracion de las caracteristicas tumorales con el indice de cancer de mama.
KR102384848B1 (ko) 2016-08-05 2022-04-08 더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 방광암용 바이오마커로서의 케라틴 17

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0088994B1 (de) 1982-03-15 1991-06-19 Schering Corporation Hybride DNS, damit hergestellte Bindungszusammensetzung und Verfahren dafür
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE447713T1 (de) * 1998-11-05 2009-11-15 Univ Michigan S100-proteine und -autoantikörper als serummarker für krebs
EP1159619A2 (de) * 1999-03-15 2001-12-05 EOS Biotechnology, Inc. Verfahren zur diagnose und zum behandeln von brustkrebs
US7585497B2 (en) 2000-05-17 2009-09-08 Oregon Health & Science University Induction of apoptosis and cell growth inhibition by protein 4.33
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
CA2472163C (en) 2012-12-18
WO2003057159A2 (en) 2003-07-17
AU2002367317A1 (en) 2003-07-24
DE60234958D1 (de) 2010-02-11
AU2002367317A8 (en) 2003-07-24
JP2005526233A (ja) 2005-09-02
WO2003057159A9 (en) 2004-06-03
EP1470239A4 (de) 2006-08-23
EP1470239B1 (de) 2009-12-30
US7465553B2 (en) 2008-12-16
EP1470239A2 (de) 2004-10-27
CA2472163A1 (en) 2003-07-17
US7776541B2 (en) 2010-08-17
ES2338774T3 (es) 2010-05-12
US20090104618A1 (en) 2009-04-23
US20030138833A1 (en) 2003-07-24
WO2003057159A3 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
Forootan et al. Prognostic significance of osteopontin expression in human prostate cancer
Saleem et al. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1
Li et al. Matrix metalloproteinase-2 and-9 expression correlated with angiogenesis in human adenomyosis
Takenoue et al. Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method
Zagars Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy
DE60234958D1 (de) Psoriasin-expression durch brustepithelzellen
Yoshida et al. Expression of survivin and matrix metalloproteinases in adenocarcinoma and squamous cell carcinoma of the uterine cervix
MXPA05001766A (es) Uso de proteina quinasa n beta.
WO2002018544A3 (en) Method and reagents for treatment of skin disorders by modulating the notch pathway
ATE532070T1 (de) Entzündungsmarker zum nachweis und zur prävention von diabetes mellitus
EP1404365A4 (de) Verfahren und zusammensetzungen zur hemmung, prävention oder verringerung des tumorzellwachstums bei patienten, die gegen die antineoplastischen wirkungen einer antiöstrogen-therapie resistent sind
CA2366682A1 (en) Tissue inhibitor of matrix metalloproteinases type-1 (timp-1) as a cancer marker
DE50207866D1 (de) Verwendung löslicher cytokeratin-1-fragmente in diagnostik
WO2004031414A3 (en) Method for diagnosing prostate cancer
Wong et al. Elevation of plasma osteopontin level in patients with undifferentiated nasopharyngeal carcinoma
DE60126248D1 (de) Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs
Chuang et al. Immunohistochemical expression of RANKL, RANK, and OPG in human oral squamous cell carcinoma
Huang et al. Serum and tissue expression of gelatinase and Twist in breast cancer.
DE50313393D1 (de) Verfahren zur diagnose von entzündungserkrankungen und infektionen mittels bestimmung von lasp-1/ lap-1
Doganavsargil et al. A comparison of p21 and p27 immunoexpression in benign glands, prostatic intraepithelial neoplasia and prostate adenocarcinoma
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
Hanada et al. Focal adhesion kinase is activated in invading fibrosarcoma cells and regulates metastasis
DE602004030824D1 (de) An der oberfläche befindliche campylobacter jejuni-polypeptide
Matsuyama et al. Gallbladder cancers rarely overexpress HER-2/neu, demonstrated by Hercep test
Mahmood et al. Matrix metalloproteinases MMP2 and MMP9 expression in stages II-III breast cancer in Iraqi women

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties